Two randomized, multicenter studies, 1 placebo-controlled and 1 dose-response, were conducted with another somatropin product in pediatric patients with idiopathic short stature. The diagnosis of idiopathic short stature was made after excluding other known causes of short stature, as well as GH deficiency. The placebo-controlled study enrolled 71 pediatric patients (55 males, 16 females) 9 to 15 years old (mean age 12 ± 1.5 years), with short stature, 68 of whom received another somatropin product. Patients were predominately prepubertal (Tanner I, 45%) or in early puberty (Tanner II, 47%) at baseline. In this double-blind study, patients received subcutaneous injections of either another somatropin product 0.222 mg/kg/week, or placebo given in divided doses 3 times per week until height velocity decreased to ≤1.5 cm/year ("final height"). Final height measurements were available for 33 subjects (22 treated, 11 placebo) after a mean treatment duration of 4.4 years (range 0.1-9.1 years).
Results are presented in Table 9. The number of patients whose final height was above the 5th percentile of the general population height standard for age and sex was significantly greater in the treated group than the placebo group (41% vs. 0%), as was the number of patients who gained at least 1 SDS unit in height across the duration of the study (50% vs. 0%).
Table 9: Baseline Height Characteristics and Effect of Another Somatropin product on Final Height in Placebo-Controlled Study, | Placebo (n=11) Mean (SD) | Another Somatropin product (n=22) Mean (SD) | Treatment Effect Mean (95% CI) | p-value |
|---|
| Baseline height SDS | -2.75 (0.6) | -2.7 (0.6) | NA | 0.77 |
| BPH SDS | -2.3 (0.8) | -2.1 (0.7) | NA | 0.53 |
| Final height SDS | -2.3 (0.6) | -1.8 (0.8) | 0.51 (0.10, 0.92) | 0.017 |
| FH SDS – baseline height SDS | 0.4 (0.2) | 0.9 (0.7) | 0.51 (0.04, 0.97) | 0.034 |
| FH SDS – BPH SDS | -0.1 (0.6) | 0.3 (0.6) | 0.46 (0.02, 0.89) | 0.043 |
The dose-response study included 239 pediatric patients (158 males, 81 females), 5 to 15 years old, (mean age 10 ± 2 years). Mean ± SD baseline characteristics included: height SDS -3.21 ± 0.70, predicted adult height SDS -2.63 ± 1.08, and height velocity
SDS -1.09 ± 1.15. All but 3 patients were prepubertal. Patients were randomized to one of three treatment groups:
0.24 mg/kg/week; 0.24 mg/kg/week for 1 year, followed by 0.37 mg/kg/week; and 0.37 mg/kg/week. Height velocity was assessed by dose during the first 2 years of therapy. After completing the initial 2-year dose-response phase of the study, 50 patients were followed to final height.
Patients who received the dosage of 0.37 mg/kg/week had a significantly greater increase in mean height velocity after 2 years of treatment than patients who received 0.24 mg/kg/week (4.04 vs. 3.27 cm/year, p=0.003). The results are presented in Table 10. While no patient had height above the 5th percentile in any dosage group at baseline, 82% of the patients who received 0.37 mg/kg/week and 47% of the patients who received 0.24 mg/kg/week achieved final heights above the 5th percentile of the general population height standards (p=NS).
Table 10: Idiopathic Short Stature Study Results: Final Height Minus Baseline Predicted Height | Placebo-controlled Trial 3× per week dosing | Dose Response Trial 6× per week dosing |
|---|
| Placebo | Another Somatropin product | Another Somatropin product | Another Somatropin product | Another Somatropin product |
|---|
| (n=10) | 0.22 mg/kg (n=22) | 0.24 mg/kg (n=13) | 0.24/0.37 mg/kg (n=13) | 0.37 mg/kg (n=13) |
|---|
FH – Baseline PH Mean (95% CI), cm | -0.7 (-3.6, 2.3) | +2.2 (0.4, 3.9) | +5.4 (2.8, 7.9) | +6.7 (4.1, 9.2) | +7.2 (4.6, 9.8) |